Basic Concepts and Indications of CAR T Cells
Hämostaseologie · 01.02.2025 · 45 (01) · 014-023
DOI: 10.1055/a-2491-3652 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Hämostaseologie, erschienen am 01.02.2025. Verfasst von Jana van den Berg und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, University Hospital Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Hematologic Neoplasms, T-Lymphocytes. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 67 Literaturangaben.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) T cell therapy has revolutionized cancer immunotherapy, particularly for hematological malignancies. This personalized approach is based on genetically engineering T cells derived from the patient to target antigens expressed—among others—on malignant cells. Nowadays they offer new hope where conventional therapies, such as chemotherapy and radiation, have often failed. Since the first FDA approval in 2017, CAR T cell therapy has rapidly expanded, proving highly effective against previously refractory diseases with otherwise a dismal outcome. Despite its promise, CAR T cell therapy continues to face significant challenges, including complex manufacturing, the management of toxicities, resistance mechanisms that impact long-term efficacy, and limited access as well as high costs, which continue to shape ongoing research and clinical applications. This review aims to provide an overview of CAR T cell therapy, including its fundamental concepts, clinical applications, current challenges, and future directions in hematological malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology, University Hospital Basel, Basel, Switzerland.
- Innovation Focus Cell Therapies, University Hospital Basel, Basel, Switzerland.
- Department of Biomedicine, University of Basel, Basel, Switzerland.
- Division of Medical Oncology, University Hospital Basel, Basel, Switzerland.
- Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.
- Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland.
ORCID-Profile: Andreas Holbro
Zitieren
APA
van den Berg, J., Läubli, H., Khanna, N., Jeker, L. T., & Holbro, A. (2025). Basic Concepts and Indications of CAR T Cells. Hämostaseologie, 45(01), 014-023. https://doi.org/10.1055/a-2491-3652
Vancouver
van den Berg J, Läubli H, Khanna N, Jeker LT, Holbro A. Basic Concepts and Indications of CAR T Cells. Hämostaseologie. 2025;45(01):014-023. doi:10.1055/a-2491-3652
BibTeX
@article{vandenBerg2025,
author = {van den Berg, Jana and Läubli, Heinz and Khanna, Nina and Jeker, Lukas T and Holbro, Andreas},
title = {Basic Concepts and Indications of CAR T Cells},
journal = {Hämostaseologie},
year = {2025},
volume = {45},
number = {01},
pages = {014--023},
doi = {10.1055/a-2491-3652}
}
EUVIMED